Literature DB >> 19029151

Medicare advantage plans at a crossroads--yet again.

Robert A Berenson1, Bryan E Dowd.   

Abstract

Since risk-taking, private health insurance plans were introduced into Medicare twenty-five years ago, policymakers have disagreed on these plans' fundamental purposes. Articulated objectives, which include improving quality, reducing government spending, providing additional benefits (without expanding the entitlement), increasing choices for beneficiaries, and providing benchmark competition for traditional Medicare, are plausible but sometimes conflicting. The program's history demonstrates continuous shifts in emphasis on these objectives. We enumerate the differing advantages of public and private plans in Medicare and argue that policymakers should focus their efforts on leveling the public-private playing field, thereby dealing forthrightly with the reality of growing fiscal problems.

Mesh:

Year:  2008        PMID: 19029151     DOI: 10.1377/hlthaff.28.1.w29

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Will Medicare Advantage payment reforms impact plan rebates and enrollment?

Authors:  Lauren Hersch Nicholas
Journal:  Am J Manag Care       Date:  2014       Impact factor: 2.229

2.  The effects of public health insurance expansion on private health insurance in urban China.

Authors:  Xiaohui Hou; Jing Zhang
Journal:  Int J Health Econ Manag       Date:  2017-02-08

3.  An economic history of Medicare part C.

Authors:  Thomas G McGuire; Joseph P Newhouse; Anna D Sinaiko
Journal:  Milbank Q       Date:  2011-06       Impact factor: 4.911

4.  Modeling the impact of Medicare Advantage payment cuts on ambulatory care sensitive and elective hospitalizations.

Authors:  Lauren Hersch Nicholas
Journal:  Health Serv Res       Date:  2011-05-24       Impact factor: 3.402

5.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.